Codagenix, Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, today announced that the Serum Institute of India has begun manufacturing CDX-005, the company's intranasal, live-attenuated vaccine candidate for SARS-CoV-2, the virus that causes COVID-19.
source https://www.pharmatutor.org/pharma-news/2020/serum-institute-of-india-initiates-manufacturing-of-codagenix-intranasal-live-attenuated-covid-19-vaccine-candidate
No comments:
Post a Comment